Aurora Cannabis ( NASDAQ: ACB ) (TSX:ACB) recently repurchased an aggregate amount of approximately C$25.3 million (US$20 million) of its convertible senior notes at a total cost, including accrued interest, of C$24.3 million (US$19.2 million) in cash. The purpose of the transaction was to reduce the company's debt and annual cash interest expense. Annual cash interest savings from note redemptions from Q3 2022 now total C$9.5 million (US$7.5 million). Aurora announced in May that it has been granted EU-GMP certification for its state-of-the-art medical cannabis production facility located in Germany. As the world's leading manufacturer of medical cannabis, obtaining EU-GMP certification for the company's first German manufacturing site marks an important milestone in completing a tender awarded by the German Federal Institute of medicines and medical devices.